These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11590487)

  • 1. The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom.
    Trueman P; Youle M; Sabin CA; Miners AH; Beck EJ
    HIV Clin Trials; 2000; 1(1):27-35. PubMed ID: 11590487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
    Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
    J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
    Mauskopf J; Lacey L; Kempel A; Simpson K
    Am J Manag Care; 1998 Jul; 4(7):1004-12. PubMed ID: 10181990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
    Bendavid E; Wood R; Katzenstein DA; Bayoumi AM; Owens DK
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):106-13. PubMed ID: 19448557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
    Simpson KN; Rajagopalan R; Dietz B
    Adv Ther; 2009 Feb; 26(2):185-93. PubMed ID: 19219410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of combination HIV therapy: 3 years later.
    Moore RD
    Pharmacoeconomics; 2000 Apr; 17(4):325-30. PubMed ID: 10947487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
    Hornberger J; Kilby JM; Wintfeld N; Green J
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
    Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
    HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the cost-effectiveness of HAART for adults with HIV in England.
    Miners AH; Sabin CA; Trueman P; Youle M; Mocroft A; Johnson M; Beck EJ
    HIV Med; 2001 Jan; 2(1):52-8. PubMed ID: 11737376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.